Celgene Gets Claims Trimmed From Andrulis Drug Patent Suit
A Delaware federal judge on Thursday trimmed Andrulis Pharmaceuticals Corp.'s suit accusing rival drugmaker Celgene Corp. of infringing its patent covering a bone marrow cancer treatment, ruling a direct infringement claim...To view the full article, register now.
Already a subscriber? Click here to view full article